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Abstract: The association between testosterone-replacement therapy and cardiovascular 
risk remains unclear with most reports suggesting a neutral or possibly beneﬁ  cial effect of 
the hormone in men and women. However, several cardiovascular complications including 
hypertension, cardiomyopathy, stroke, pulmonary embolism, fatal and nonfatal arrhythmias, 
and myocardial infarction have been reported with supraphysiologic doses of anabolic steroids. 
We report a case of an acute ST-segment elevation myocardial infarction in a patient with 
traditional cardiac risk factors using supraphysiologic doses of supplemental, intramuscular 
testosterone. In addition, this patient also had polycythemia, likely secondary to high-dose 
testosterone. The patient underwent successful percutaneous intervention of the right coronary 
artery. Phlebotomy was used to treat the polycythemia acutely. We suggest that the chronic 
and recent “stacked” use of intramuscular testosterone as well as the resultant polycythemia 
and likely increased plasma viscosity may have been contributing factors to this cardiovascular 
event, in addition to traditional coronary risk factors. Physicians and patients should be aware 
of the clinical consequences of anabolic steroid abuse.
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Supraphysiologic doses of anabolic-androgenic steroids (AAS), which include more 
than 30 natural and synthetic derivatives of testosterone, may cause a wide spectrum 
of clinical sequalae. There have been a few case reports in the literature suggesting an 
association of intracoronary thrombosis, sudden death, myocardial necrosis, stroke and 
cardiomyopathy as possible sequelae of the use of supraphysiologic doses of anabolic 
steroids (McNutt et al 1988; Nieminen et al 1996; Dhar et al 2005).
The use of testosterone supplementation in physiologic doses has expanded in 
the last decade to include indications, such as stimulation of appetite in cachexia, 
improvement in libido and mood, as well as treatment of hypogonadism (Rhoden and 
Morgentaler 2004). Moreover, testosterone has been used in the treatment of reduced 
muscle mass and bone density as well as anemia. The role testosterone may play in 
the development of cardiovascular disease has increasingly become the subject of 
current interest (Choi and McLaughlin 2007). Although the data for physiologic doses 
of testosterone replacement therapy have not demonstrated an increased incidence of 
cardiovascular event, long-term effects on cardiovascular health requires prospective, 
large-scale, randomized trials.
Testosterone stimulates erythropoiesis, particularly in high doses (Fried and Gurney 
1968). Drastic elevations of hematocrit may be detrimental to patients with underlying 
coronary, cerebral or peripheral vascular disease by possibly causing an increase in 
blood viscosity (Basaria and Dobbs 1999; Viallard et al 2000), and increased risk Vascular Health and Risk Management 2008:4(6) 1476
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of  thrombosis. We present a case of an acute inferior wall 
ST segment myocardial infarction in a patient using high 
dose testosterone with associated polycythemia.
Case report
A 44-year-old male without prior cardiac history presented 
with one day of intermittent exertional, substernal chest pain 
culminating in rest angina. He described associated features 
of left shoulder pain, shortness of breath and diaphoresis. He 
was taking high-dose intramuscular testosterone for the previ-
ous six weeks, and intermittently for two years. In addition, 
he was taking sildenaﬁ  l occasionally. He was a recreational 
weight-lifter. His cardiac risk factors included tobacco 
abuse and family history of early coronary artery disease. 
There was no family history of lipid disorder. His physical 
examination was remarkable for his muscular appearance 
and a blood pressure of 190/100. He was in mild distress 
with no signs of heart failure. His blood chemistry revealed a 
creatinine of 1.3 mg/dl and elevated liver enzymes (aspartate 
aminotranferease 86 units/L, and alanine aminotransferase 
79 units/L). Hematologic studies noted an hemoglobin of 
22 g/dl and hematocrit of 63%. His platelet count was normal 
with a mildly elevated white blood count. His creatinine 
kinase (CK), CK-MB, and troponin were within normal 
limits on presentation. An electrocardiogram revealed sinus 
bradycardia, left ventricular hypertrophy, an acute inferior 
injury pattern with ST-segment elevation, and anterolateral 
ischemia. Ventricular bigeminy was also noted (Figure 1). 
Emergent cardiac catheterization was then performed via 
the right femoral artery. Selective left coronary angiography 
revealed a diffusely diseased left anterior descending artery 
(LAD) with a 95% lesion after the takeoff of a small septal 
branch (Figure 2). The circumﬂ  ex artery was free of signiﬁ  -
cant disease. Selective right coronary angiography revealed 
a total occlusion at the mid-portion of the vessel with 
intracoronary thrombus (Figure 3). The patient underwent 
percutaneous transluminal coronary angioplasty (PTCA) and 
stent placement in the mid and distal right coronary artery 
vessel. The right coronary artery was notably a large, domi-
nant vessel (Figure 4). The procedure was complicated by 
distal embolization, treated with intracoronary adenosine and 
glycoprotein IIb/IIIa inhibitor, which resulted in some angio-
graphic improvement. Clopidogrel (300 mg loading dose and 
75 mg thereafter) was initiated immediately. The patient’s 
peak CK and CK-MB were 8830 units/L and 1800 units/L, 
respectively. A transthoracic echocardiogram demonstrated 
that the patient’s left ventricular systolic function was mod-
erately reduced with inferior and inferoseptal akinesis, and 
inferolateral hypokinesis. The ejection fraction was 35%. 
Successful percutaneous intervention and stent placement 
were performed on the lesion in his left anterior descending 
artery on the following day. The patient was phlebotomized 
until his resultant hematocrit was 45%. Hematological 
workup for malignancy was negative. Total cholesterol was 
219 mg/dl, low-density lipoprotein (LDL) cholesterol was 
154 mg/dl, and high-density lipoprotein (HDL) 50 mg/dl. 
Figure 1 The patient’s electrocardiogram on presentation.Vascular Health and Risk Management 2008:4(6) 1477
Anabolic steroids, acute myocardial infarction, and polycythemia
Figure 2 An anterior-posterior view of the left coronary system.   The left anterior artery demonstrates a 95% stenosis after the ﬁ  rst septal branch.
Figure 3 A left anterior oblique view of the right coronary system, demonstrating a total occlusion of the mid right coronary artery with thrombus.Vascular Health and Risk Management 2008:4(6) 1478
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Standard medical therapy for acute myocardial infarction 
was initiated following the intervention and included aspirin, 
clopidogrel, beta-blocker, statin, and angiotensin converting 
enzyme inhibitor.
Discussion and review
of the literature
Anabolic androgenic steroid use has increased over the 
past decade, despite its potential for adverse effects. They 
continue to be used by Olympic level athletes, and have 
even spread to high school level athletes, noncompetitive 
bodybuilders and recreational athletes (Sullivan et al 1998; 
Dhar et al 2007). Unfortunately, the data on the use of high 
dose anabolic steroids in humans are mainly offered as case 
reports or small studies that lack adequate control groups. In 
addition, the data available in the literature does not account 
for the steroid type(s) or dose, as neither may be known. 
Patients also may be taking concomitant stimulants, such 
as ephedra, which can confound data and the potential for 
adverse events. It is likely that the frequency of cardiac events 
is underreported in the medical literature.
Supplemental or physiologic doses of testosterone 
have noticed expanded use in medical practice recently. 
Testosterone is a potent ligand of the human androgen receptor 
and therefore, can modulate cellular functions such as tran-
scription, translation and enzymatic function in skeletal and 
myocardial tissue. However, these functions can affect numer-
ous other tissues. Other common potential adverse effects 
include infertility, hepatotoxicity, psychological abnormali-
ties, and gynecomastia (Rhoden and Mortgentaler 2004).
Several case reports describe the deleterious cardiac 
effects of anabolic steroids including its potentially athero-
genic and thrombotic properties. These range from lipid 
disorders to acute myocardial infarction and sudden cardiac 
death (Kennedy and Lawrence 1993; Hourigan et al 1998; 
Fineschi et al 2001; Wysoczanski et al 2008). Thromboem-
bolic phenomenoma, intracardiac and peripherally, have 
been described (McCarthy et al 2000). Cardiomyopathy, 
cardiomegaly and biventricular dilatation have been asso-
ciated with AAS use. Mewis and colleagues (1996) dem-
onstrate a case report of a young bodybuilder with severe 
coronary artery disease with a two-year history of chronic 
anabolic steroid use. A case control study of 62 male com-
petitive powerlifters notes a possible increase in premature 
mortality compared with controls (12.9% versus 3.1%) 
Parssinen et al 2000).
Figure 4 A left anterior oblique view of the right coronary artery after percutaneous intervention.Vascular Health and Risk Management 2008:4(6) 1479
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Potential mechanisms of cardiovascular toxicity of AAS 
include: atherogenic, thrombotic, vasospastic, and direct 
myocardial injury. The atherogenic model involves changes 
to lipid metabolism, including reductions in HDL levels and 
elevations in LDL (Melchert and Welder 1995; Feller et al 
2003). Although difﬁ  cult to quantitate, the increased risk of 
cardiac disease may be as high 3-fold among individuals who 
use AAS (Melchert and Welder 1995; Sullivan et al 1998).
Development of an atheromatous plaque perpetuates 
endothelial dysfunction and promotes platelet aggregation 
and intracoronary thrombus formation (Ajayi et al 1995; 
Nieminen et al 1996). AAS may cause a hypercoagulable 
state, by an increase in production of thromboxane A2 and 
platelet thromboxane A2 receptor density as well as aggrega-
tion responses and a decrease in production of prostaglandins 
(Ajayi et al 1995). Moreover, a component of endothelial 
dysfunction has been proposed, which may contribute to 
abnormal vessel reactivity. However, testosterone in physi-
ologic doses may even be beneﬁ  cial in patients with angina 
(English et al 2000), have higher ischemic thresholds and 
improved quality of life (Malkin et al 2004). Short-term 
intracoronary administration of testosterone induces coronary 
artery dilation and increases coronary blood ﬂ  ow in men 
with established coronary artery disease (Webb et al 1999). 
Therefore, an interplay of endogenous factors of the patient’s 
risk proﬁ  le as well as the testosterone dosing may be issues 
of whether adverse events occur.
Direct myocardial cell injury may occur by disruption 
of mitochondria and induction of intraﬁ  brillar collagen 
dysplasia (Melchert and Welder 1995; Sullivan et al 1998). 
Cellular injury results in ﬁ  brosis, which can be a poten-
tial nidus for ventricular arrhythmias. Patients commonly 
develop left ventricular hypertrophy, which may be related 
to hypertension, another adverse effect of AAS.
Erythrocytosis has been reported as a potential effect of 
testosterone, which can be beneﬁ  cial in patients with anemia. 
However, dramatic elevations in hematocrit may be detri-
mental to patients with underlying coronary artery disease, 
as this may increase blood viscosity (Basaria and Dobbs 
1999; Viallard et al 2000). The greatest risk of erythrocytosis 
occurs with injectable forms of testosterone compared with 
transdermal preparations, especially in supraphysiologic 
doses. An increase of up to 44% of the baseline hematocrit 
has been reported (Dobs et al 1999).
We report for the ﬁ  rst time an unusual case of an acute 
ST segment elevation myocardial infarction immediately 
following supraphysiologic “stacked” doses of intramuscular 
testosterone in a patient with known risk factors for coronary 
artery disease with associated dramatic polycythemia. 
We propose an association and potential interplay of tradi-
tional cardiovascular risk factors, high dose testosterone use, 
and possibly elevated plasma viscosity as possible contribu-
tors to this cardiovascular event (Basaria and Dobbs 1999; 
Viallard et al 2000).
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